58481-11-1

Basic information

• Product Name: METHYL 2-CHLOROISONICOTINATE
• Synonyms: 2-CHLORO-ISONICOTINIC ACID METHYL ESTER;BUTTPARK 91\04-05;METHYL 2-CHLOROISONICOTINATE;METHYL 2-CHLOROPYRIDINE-4-CARBOXYLATE;METHYL 2-CHLORO-4-PYRIDINECARBOXYLATE;Methyl 2-chloroisonicotinate ,98%;4-Pyridinecarboxylic acid, 2-chloro-, methyl ester;Methyl 2-chloroisonicotin...
• CAS NO: 58481-11-1
• Molecular Formula: C₇H₆ClNO₂
• Molecular Weight: 171.58
• Product Categories: blocks;Carboxes;Pyridines;Esters;Pyridine;Picolinic acid series;alkyl chloride|carboxylic ester
• Mol File: 58481-11-1.mol

Chemical Properties

• Melting Point: 32-36 °C
• Boiling Point: 70°C/0.1mmHg(lit.)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.294 g/cm³
• Vapor Pressure: 0.018mmHg at 25°C
• Refractive Index: 1.531
• Storage Temp.: 2-8°C
• PKA: -1.15±0.10(Predicted)
• CAS DataBase Reference: METHYL 2-CHLOROISONICOTINATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-CHLOROISONICOTINATE(58481-11-1)
• EPA Substance Registry System: METHYL 2-CHLOROISONICOTINATE(58481-11-1)

Safety Data

• Hazard Codes: Xi
• Statements: 37/38-41
• Safety Statements: 26-36/39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 58481-11-1(Hazardous Substances Data)

Usage

Chemical Properties

White to light brown solid

InChI:InChI=1/C7H6ClNO2/c1-11-7(10)5-2-3-9-6(8)4-5/h2-4H,1H3

Upstream product

• 6313-54-8 2-chloroisonicotinic acid, 
• 67-56-1 methanol 
• 3783-38-8 methyl isonicotinate N-oxide 
• 65287-34-5 2-chloropyridine-4-carbonyl chloride 
• 74-88-4 methyl iodide 
• 34472-65-6 (trimethylsilyl)diazomethane 

Downstream Products

• 58481-04-2 2-chloroisonicotinic acid hydrazide 
• 119836-24-7 methyl 3-(2-chloropyridin-4-yl)-3-oxopropanoate 
• 42729-22-6 2-(3-trifluoromethylphenyl)amine-4-pyridinecarboxylic acid 
• 85726-32-5 methyl 2-[[3-(trifluoromethyl)phenyl]amino]isonicotinate 
• 85726-26-7 2-chloro-4-(N-4-chlorophenyl)pyridinecarboxyamide 
• 85726-31-4 methyl 2-((4-chlorophenyl)amino)isonicotinate 
• 85726-33-6 2-(4-Methoxy-phenylamino)-isonicotinic acid methyl ester 
• 85726-25-6 2-chloro-4-(N-3,4-dichlorophenyl)pyridinecarboxyamide 
• 85726-28-9 2-(3,4-dichlorophenyl)amine-4-pyridinecarboxylic acid 
• 85726-27-8 2-(3,4-dichlorophenyl)amine-4-(N-3,4-dichlorophenyl)pyridinecarboxyamide 
• 85726-30-3 2-(3,4-Dichloro-phenylamino)-isonicotinic acid methyl ester 
• 935265-50-2 methyl 2-(2-(1-(tert-butyldimethylsilyloxy)-7-phenylheptyl)oxazol-5-yl)isonicotinate 
• 220340-37-4 4-hydroxymethyl-2,2'-bipyridine 
• 1748-89-6 2,2'-bipyridine-4-carboxylic acid 

Relevant articles and documents

FLUOROINDOLE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor.(Formula I) (I)

INHIBITORS OF HEPATITIS C VIRUS POLYMERASE

The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

Synthesis, biological evaluation and molecular docking studies of novel 2-(1,3,4-oxadiazol-2-ylthio)-1-phenylethanone derivatives

In present study, a series of new 2-(1,3,4-oxadiazol-2-ylthio)-1- phenylethanone derivatives (6a-6x) as potential focal adhesion kinase (FAK) inhibitors were synthesized. The bioassay assays demonstrated that compound 6i showed the most potent activity, which inhibited the growth of MCF-7 and A431 cell lines with IC50 values of 140 ± 10 nM and 10 ± 1 nM, respectively. Compound 6i also exhibited significant FAK inhibitory activity (IC50 = 20 ± 1 nM). Docking simulation was performed to position compound 6i into the active site of FAK to determine the probable binding model.

THIAZOLE AND OXAZOLE KINASE INHIBITORS

The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

METHODS FOR TREATING CHRONIC PAIN USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS

Disclosed herein are methods of treating a patient suffering from one or more types of chronic pain using compounds of Formulas 1 and 2 wherein the variables have the meaning disclosed in the specification

Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, G, J, K, L, M, W, V, R2, R3, R4, R5, R5a,

Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof

The present invention relates to pyrazolo[1,5-a]pyrimidine derivatives, compositions comprising an effective amount of a pyrazolo[1,5-a]pyrimidine derivative and methods for treating or preventing cancer, comprising administering to a subject in need thereof an effective amount of a pyrazolo[1,5-a]pyrimidine derivative.

SELECTIVE INHIBITORS AGAINST Cdk4 AND Cdk6 HAVING AMINOTHIAZOLE SKELETON

The present invention relates to a compound represented by Formula [I]: wherein X is O, S, NH or CH 2 ; Y 1 , Y 2 , Y 3 , Y 4 and Y 5 , which may be identical or different, are each CH or N; however, at least one of Y 1 , Y 2 , Y 3 , Y 4 and Y 5 is N; Z 1 and Z 2 , which may be identical or different, are each CH or N; n is an integer from 1 to 3; R 1 is a C 3 -C 8 cycloalkyl group, a C 6 -C 10 aryl group, an aliphatic heterocyclic ring or an aromatic heterocyclic ring, or a bicyclic aliphatic saturated hydrocarbon group; R 2 and R 3 , which may be identical or different, are each a hydrogen atom, a lower alkyl group, a lower alkenyl group, a C 3 -C 8 cycloalkyl group, a C 6 -C 10 aryl group, an aromatic heterocyclic ring, or the like; and R 4 is a hydrogen atom, a lower alkyl group, a C 3 -C 6 cycloalkyl group or the like, or a pharmaceutically acceptable salt or ester thereof, and a selective inhibitor against Cdk4 and/or Cdk6 or an anticancer agent containing the compound or a pharmaceutically acceptable salt or ester thereof.

2-PHENYLPYRIDINE DERIVATIVE

The present invention relates to a novel 2-phenylpyridine derivative or a salt thereof, wherein the pyridine ring is substituted with a carboxyl group or the like and the benzene ring has an electron-withdrawing group such as a cyano group and an electron-donating group such as a substituted alkoxy group at the same time. Since the compound of the invention has good xanthine oxidase-inhibitory action and uric acid-lowering action and does not have a structure derived from nucleic acid, the compound has advantages of high safety and excellent effects as compared with conventional compounds and is useful as a therapeutic or preventive agent for hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy, or the like.

NOVEL INHIBITORS OF PROTEIN KINASE

The present invention relates to novel compounds for inhibition of angiogenesis receptor tyrosine kinases, in particular, VEGF receptor 2 kinase ("KDR") activity, and preparations for preparation of them, and the use of them, and pharmaceutical compositions containing them at a therapeutically effective amount. The compounds according to the present invention are useful for the treatment and prevention of diseases resulting from the undesired KDR activity, for example, angiogenesis-related diseases such as cancers, psoriasis, rheumatoid arthritis, diabetic retinopathy, etc.